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Introduction  
 
The purpose of this review was to assess the evidence for the use of HBOT to treat soft tissue 
injuries, including DOMS, and closed fractures. It was a report commissioned by City Football 
Services to help understand whether using HBOT was safe, effective, what parameters are required 
and what conditions could be treated using HBOT. 
 
 
HBOT Theory  
 
Hyperbaric oxygen therapy (HBOT) is a process involving the use of a hyperbaric chamber to reach 
pressures greater than local atmospheric pressure to treat injury or disease (Sjoberg & Singer, 
2013). The therapy is carried out using mono-place (single person) or multi-place (multiple person) 
chambers. Multi-place chambers are pressurised by air, and oxygen is delivered via a face-mask, 
endotracheal tubes or head hoods. Near 100% oxygen is used to pressurise smaller mono-place 
chambers and thus the patient directly breathes the ambient chamber oxygen.   
 
The pressure of the surrounding medium, such as gas or liquid, coming into contact with the object 
is known as ambient pressure. This pressure is measured using the pascal (Pa). When using 
hyperbaric therapy ambient pressure is more commonly measured in atmospheres (ATA or ATM). 
Atmospheric pressure at sea level is 1 ATA; at 10m depth in sea water is 2 ATA; and at 20m depth is 
3 ATA (Mills, 2012).  According to the Undersea & Hyperbaric Medical Society (UHMS) in order to 
constitute HBOT, the person must inhale 100% oxygen with pressurisation at 1.4 ATA or higher 
(Hampson, 1999). The restorative effects of HBOT are the result of an elevation in dissolved oxygen 
in plasma and tissue oxygen delivery (Thom, 2011). Delivery of 100% oxygen over or equal to 60 
minutes with a pressure at 1.4 atmospheric absolute (ATA) has previously been reported to be 
beneficial for the rate of recovery after injury (Thom, 1992). 
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Physiological and biochemical effects of HBOT 
 
The efficacy of HBOT is established through the biochemical and physiological effects of hyperoxia. 
The effect of HBOT is based on the gas laws: Daltons, Boyle’s and Henry’s Law (Gill & Bell, 2004) 
Henry’s law is the basis for elevated tissue oxygen tensions found with HBOT, stating that, "At a 
constant temperature, the amount of a given gas that dissolves in a given type and volume of liquid 
or tissue is directly proportional to the partial pressure of that gas in equilibrium with that liquid or 
tissue.”  
 
Oxygen is transported by blood chemically binding to haemoglobin and physically by dissolving in 
plasma. During normal respiration at atmospheric pressure the oxygen bound to haemoglobin has 
an oxygen saturation of 97-99%. The additional oxygen carried within the plasma as a result of 
Henry’s law, further enhances the oxygenation of tissues.  The arterial oxygen tension and tissue 
oxygen tension are 100 millimetre of mercury (mmHg) and 55 mmHg, respectively, with a plasma 
oxygen concentration of 3ml/l, when breathing normobaric air (normal barometric pressure 
equivalent to that at sea level). However, when at a hyperbaric level; e.g. 100% oxygen at 3 ATA, 
arterial oxygen tension and tissue oxygen tension are increased to approximately 2000 mmHg and 
500mmHg, respectively, with a dissolved plasma oxygen concentration close to 60 ml/l (Leach et al, 
1998). In conditions where haemoglobin oxygen carriage is obstructed, the oxygen carried within 
the plasma is able to pass. 
 
Research into the physiological effects of hyperoxia has found that blood flow is suddenly reduced 
as a result of the sudden vasoconstriction of vessels. However, with increased oxygen plasma 
carriage through use of HBOT, blood flow to ischaemic tissue is enhanced. Increased levels of post-
traumatic, tissue oedema found in compartment syndrome and crush injuries, can be significantly 
reduced with the assistance of vasoconstriction (Mortensen, 2008). Additional HBOT short term 
effects include an elevated leukocyte function and phagocytosis by improving the local 
microcirculation through the destruction of bacteria, all contributing to the anti-inflammatory 
effect. Late stage healing effects contribute to neovascularization (expansion of microvascular 
networks), through synthesis of growth factors and angiogenesis (local endothelial cells aid growth 
of new blood vessels) (Simsek et al, 2011). HBOT also stimulates synthesis of fibroblast collagen 
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production and osteogenesis (Hunt, 1990, Zamboni et al, 1993; Hopf & Rollins, 2007; Soneja et al, 
2005; Bosco et al, 2009). 
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HBOT Mechanisms of Action: 
 
 Reactive Vasoconstriction: Oedema is reduced whilst normal tissue oxygen is maintained  
through the contraction of small vessels that are constricted (Mortensen, 2008). 
 Healing effect: improves and intensifies the growth of osteoclasts and osteoblasts, increases 
the synthesis of collagen and encourages angiogenesis in hypoxic tissues, thus increasing 
healing in chronic wounds osteradionecrosis and burns (Kang et al, 2004).
 
 
 Oxygen pressure increase: aids removal of toxic gases (carbon monoxide) because when 
high concentrations of oxygen are present in alveolar air carbon monoxide is displaced from  
haemoglobin faster than ambient air pressure  (Weaver et al, 2002; Garrrabou et al, 2011). 
 Antibacterial effect: - ensures oxygenation of antibacterial defences (Kendall et al, 2012). 
 Action: Gas embolism and decompression sickness is treated by reducing the pressure 
volume of gas bubbles (Thom, 2008). 
 
The incidence of sporting injuries has increased as a result of the increased intensity of elite and 
recreational competitive sport. These sporting injuries may include fractures to the bone, and /or 
muscle, ligament and tendon damage. 
  
Reduced stability, significant gaps at the fracture site, infection, reduced vascularity all impede the 
fracture healing process. Treatment aims to improve the structural integrity of the fracture site. 
However, the management of fractures can be frequently impaired as a result of delayed or non-
union, leading to a significant loss of function (Birnbaum, 2002).  
 
A number of treatment approaches have been adopted to establish osteogenesis (bone generation), 
provide stability and reduce fracture gaps. Methods used include internal and external fixation, 
bone grafting electrical stimulation and extracorporeal shockwave therapy (Gallay & Mckee, 2000; 
Biedermann et al 2003; Karamitros et al, 2006). HBOT has been used in the past for treatment of 
bone fractures but the evidence support its positive effect remains anecdotal. 
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Injuries affecting the soft tissue are common and may include anything from minor bruising to 
serious damage to the ligament, tendon and muscles. The cause of such injuries may range from 
overuse and repetitive strain to traumatic injuries. In addition, and commonly as a result of 
unaccustomed exercise, is delayed onset of muscle soreness (DOMS) which may present as slight 
muscle soreness up to significant pain and swelling. 
 
The potential of HBOT to accelerate the healing process through the reduction of inflammation and 
local tissue hypoxia has interested the sports medicine field. Despite no conclusive scientific 
evidence to support the use of HBOT for sports injuries, hyperbaric chambers have been purchased 
by a number of professional sport facilities. HBOT was seen as a treatment approach to accelerate 
the recovery process, enabling the athlete to return to competition / training.  
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What Is HBOT Used For? 
 
Hyperbaric oxygen therapy is used in the treatment of a number of conditions; in some cases it may 
be used as the primary therapy intervention, whereas in others as an adjunct to pharmacology or 
surgery. Cochrane reviews have addressed the use of HBOT in a number diseases / conditions 
(Kranke et al, 2012; Eskes et al, 2013; Levett et al, 2015). However, in general, the quality and 
number of trials have been considered insufficient to draw definite conclusions (Sjoberg & Singer, 
2013).  
 
The US Food and Drug Administration (FDA) and UHMS has cleared 14 indications for the safe use of 
HBOT. Idiopathic sudden sensorineural hearing loss being the most recent addition having been 
approved on October 2011 by the UHMS. Oxygen has often been used, and its efficacy claimed, 
without the need to titrate the dose (Sjoberg & Singer, 2013). 
 
Due to the limited evidence to support the use of HBOT for closed soft tissue injury, DOMS and 
fractures, they have not been cleared by the FDA and UHMS.  
 
 
Air or Gas Embolism  
 
Air or gas embolism occurs when air bubbles form in the circulation. A common cause is pulmonary 
barotrauma which can be seen on returning to the surface after breathing compressed gas at depth 
(in water), and also during mechanical ventilation (Murphy et al, 1985; Hampson 1999).  
 
As stated in Boyle’s law, the volume of gas is inversely proportional to pressure, the bubble volume 
is reduced with increased pressure (Benson et al, 2003).  Case studies and UHMS suggests that 
there is 100% oxygen at 2.8 ATA.   Repeating using these parameters for 5 to 10 treatments until no 
evidence of further improvement would offer the greatest benefit for the treatment of air or gas 
embolism, as recommended by the UHMS (Hampson, 1999 & Benson et al, 2003 Gesell, 2008). 
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Carbon Monoxide Poisoning  
 
Carbon monoxide poisoning can cause many delayed neurological problems including chronic 
headaches, cognitive deficits and Parkinson's Disease (Thom et al, 1995, Weaver et al, 2002).  
HBOT helps to separate carbon monoxide from haemoglobin and increases the oxygenation of 
tissues and helps decrease the incidence of delayed neuropsychological sequelae (Thom, 1995; 
Leach et al, 1998). Recommended parameters used during previous research and recommended by 
UHMS are 100% oxygen and between 2.4 ATA and 3.0 ATA. Number of session suggested - until 
symptoms resolved  (Thom et al, 1995 & Hampson, 1999, Gesell 2008). 
 
 
Clostridial Myositis and Myenonecrosis (Gas Gangrene) 
 
Clostridial myositis and myenonecrosis is an acute rapid invasive infection of the muscles causing 
oedema, tissue destruction and toxemia (Stevens, 2000). The infection is caused by germinating 
clostridial spores within the tissue (Stevens, 2000). HBOT is used in addition to tissue debridement 
to help reduce bacteria and toxins. Treatment in the first 24hrs should include 3 x 90 minute 
treatments with 100% oxygen at 3 ATA. It is suggested that the initial treatments should be 
followed by twice-daily treatments for a further 4-5 days (Hampson, 1999; Gesell, 2008). 
 
 
Crush Injury, Compartment Syndrome and other Acute Traumatic Ischaemias  
 
Crush injuries can involve multiple tissue trauma including joints, bones, tendons, muscles and skin. 
Further complications following trauma may arise including: non-union of fractures, osteomyelitis, 
compartment syndrome and failed flaps (Wattel et al, 1998). HBOT is used to regain tissue oxygen 
tensions through the increase of plasma-based oxygenation, in addition to stimulating the synthesis 
of collagen and fibroblast facilitating angiogenesis (Zamboni et al, 1993, Strauss et al, 1983). 
 
With the introduction of hyperoxia in conditions such as compartment syndrome the cycle of 
ischaemia and oedema is resolved without impairing the delivery of oxygen as a result of 
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vasoconstriction (Nylander et al, 1985). Treatment is carried out once per day for several days 
dependent on the level of injury and advised to take place within 4-6hrs post injury using 100% 
Oxygen at 2.0 - 2.5 ATA once per day (Hampson, 1999; Gesell, 2008). 
 
 
Decompression Sickness  
 
Decompression sickness occurs when, due to supersaturation, inert gas (commonly nitrogen) forms 
within the tissue and capillaries (Brubakk, 1999).  Supersaturation and bubble formation occurs 
when the inert gas partial pressure of the tissues exceeds the ambient pressure (Carturan et al, 
2002). Symptoms can include joint pains, neurological complaints, shock and death as a result of the 
occlusion of vessels and tissue disruption (Hagberg & Ornhagen, 2003). 
 
Using HBOT to administer oxygen at greater ambient pressure is said to reduce the bubble volume 
(Zamboni, 1993). HBOT repeated up to 10 times of 100% oxygen at 2.8 ATA has been recommended 
(Hampson, 1999, Gesell, 2008). 
 
 
Arterial insufficiencies - Enhancement of healing in selected problem wounds  
 
HBOT is frequently used for the treatment of problem wounds including insufficiency ulcers and 
diabetic foot ulcers (Abidia et al, 2003).Healing is impaired by a reduction in bacterial killing, 
phagocytosis and lymphocytes (WBC) (Simsek et al, 2011).  
 
HBOT at 100% oxygen and increased atmospheric pressure results in an increase plasma volume 
and therefore transportation of oxygen enhancing wound healing through increased oxygenation, 
fibroblast growth, collagen synthesis and neovascularisation (Baroni et al, 1987 & Hunt, 1990).  
Significantly higher rates of wound healing were found using HBOT following a randomised 
controlled trial (RCT) including 100 patients with diabetic foot ulcers, that had failed to respond to 
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other treatments (Duzgun et al, 2008). These findings have been supported by further RCTs 
demonstrating wound healing and wound size reduction (Londahl et al, 2010 & Ma et al, 2013).  
 
UHMS recommend 90-120mins, once a day, up to 30 treatments of 100% oxygen at 2.0-2.5 ATA 
(Hampson 1999; Gesell, 2008). These parameters were also used during RCTs (Abidia et al, 2003 & 
Ma et al, 2013) 
 
 
Severe Anaemia  
 
A major loss of red blood cells causing limited oxygen carriage as a result of haemolysis or 
haemorrhage results in tissue hypoxia leading to ischaemia (Leach et al, 1998). In these situations, 
and where transfusions are not possible, e.g. rare blood group or religious beliefs, HBOT may be 
used to increase levels of oxygen dissolved in plasma, compensating for reduced haemoglobin 
levels.  
 
Treatment periods of 2 - 4 hours, three to four times per day of 100% oxygen up to 3 ATA have been 
recommended by the UHMS (Hampson, 1999, Gesell, 2008) 
 
 
Intercranial Abscess 
 
Improved diagnosis and therapy in conditions including subdural empyema, cerebral abscess have 
decreased the mortality rate related to them. HBOT may be used in circumstances where patients 
have failed to respond to standard care. HBOT can modify the immune response and reduce 
cerebral oedema.  
 
Despite limited clinical evidence UHMS recommend treatment sessions between 60-90 minutes of 
100% oxygen at 2.0-2.5 ATA and up to 20 sessions  (Hampson, 1999; Gesell, 2008). 
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Necrotising Soft Tissue Infections  
 
Necrotising soft tissue infections are infections of the deep fascia in addition to involvement of 
subcutaneous and cutaneous layers. Tissues become hypoxic, hypo-cellular and hypo-vascular. A 
Cochrane review on adjunctive hyperbaric oxygen for necrotising fasciitis (Levett et al., 2015) 
screened 673 records and found no studies eligible for assessment. A retrospective cohort study 
found limb salvage and improved survival from necrotising soft tissue infection using HBOT 
(Wilkinson & Doolette, 2004).  
 
UHMS recommends 100% oxygen at 2.0-2.5 ATA twice a day, with a reduction to one per day when 
symptoms are reduced. The recommendation is to treat until symptoms are resolved with a review 
at 30 sessions (Hampson, 1999, Gesell, 2008). 
 
 
Osteomyelitis (Refractory) 
 
Osteomyelitis is a bacterial infection of the bone. HBOT has been recommended in cases of 
osteomyelitis, in addition to debridement and antibiotics (Hampson, 1999, Gesell, 2008). Standard 
treatment for Osteomyelitis is antibiotic prophylaxis and surgical debridement (Gill & Bell, 2004; 
Eckardt et al, 1994).  
 
Oxygen tension in normal bone under ambient conditions is approximately 45mmHg. In bone with 
chronic osteomyelitis a 50% reduction in oxygen tension has been reported (Galhoun et al, 1991). In 
order to maintain neovascularisation oxygen tensions of 30 to 40 mmHg are required (Hohn et al, 
1976). 
 
HBOT increases tissue oxygen tension increasing the synthesis of collagen and angiogenesis 
(Knighton et al, 1981).  It has been reported that as a result of hypoxia and associated alterations in 
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oxygen tensions, osteoclast (re-absorbs bone) formation is increased and osteoblast (forms bone) 
activity is suppressed. HBOT is said to restore the elevated  oxygen tension in infected bone and in 
hypoxic tissue anaerobic organism growth is inhibited (Davies et al, 1986). 
 
HBOT, wound debridement and antibiotics proved successful in freeing 34 out 38 patients from 
osteomyelitis for a period of 34 months (Davis, et al, 1986). In a retrospective study by Chen et al 
(2003) 11 out of 14 patients with tibial osteomyelitis were treated successfully and safely with 
HBOT.  
 
The number of sessions is usually defendant on the osteomyelitis severity. In conjunction with 
antibiotics, debridement the UHMS recommends daily treatments from 90-120mins of 100% oxygen 
at 2.0-2.5 ATA and up to 40 treatments (Hampson, 1999; Gesell, 2008). 
 
 
Delayed Radiation Injury (soft tissue and bone necrosis) 
 
Radiotherapy is used in high doses to eliminate tumours often causing a degree of cellular 
impairment, leading to tissue hypoxia. Osteoradionecrosis (ORN) is consistent with head and neck 
cancer patients receiving high doses of radiation. HBOT may be used to treat and halt the 
progression of ORN, increasing tissue oxygen tensions to sufficient levels to enable angiogenesis 
and improved leukocyte function (Hunt, 1990). 
 
The evidence for the use of HBOT for delayed radiation injury is extensive albeit limited to lower 
levels of evidence. In a study comparing penicillin to HBOT Marx et al, (1985) found HBOT to be 
more effective in the prevention of osteonecrosis before tooth extraction. A review by Lubek et al, 
(2013) on the value of HBOT in treating ORN suggested that guidelines for the effective use of HBOT 
have yet to be established. 
 
Evidence remains limited and there is only one prospective, double blinded, randomised, controlled 
trial comparing HBOT with placebo for mandibular ORN. As there was no evidence to support the 
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effectiveness of HBOT the trial was discontinued (Annane et al, 2004). 56% of patients with exposed 
bone were included in the study, a small sample size and HBOT not being standardised in the 
experimental group led to criticism of the study (Lubek et al, 2013).  
 
Despite the existence of no clear evidence to support the use of HBOT in the treatment of delayed 
radiation therapy it has been recommended by UHMS that 100% oxygen at 2.0-2.5 ATA with 
sessions lasting 90-120 minutes for up to 40 days be administered  (Hampson, 1990; Gesell, 2008).  
 
 
Compromised Grafts and Flaps  
 
HBOT has been established as a proven means of skin flap and graft survival in a number of animal 
studies (Baynosa & Zamboni, 2012). In tissues compromised by decreased perfusion or hypoxia, 
HBOT can be useful in flap / graft salvage.  
 
A number of clinical studies have denigrated the effective use of HBOT when managing 
compromised  skin flaps and grafts (Perrins, 1967; Gonnering et al, 1986; Waterhouse et al, 1993). 
It is recommended that HBOT of 100% oxygen for 90 - 120 minutes at 2.0 - 2.5 ATA be used for 
compromised skin flaps and grafts with 2 treatments per day, before reducing to 1 per day on 
stabilisation of graft and treatment review after 20 treatments (Hampson, 1990; Gesell, 2008; 
Baynosa & Zamboni, 2012). 
 
 
Acute Thermal Burn Injury  
 
Insufficient oxygen and nutrient supply leads to a rapid deterioration to a central area of 
coagulation found with severe burns (Bhutani & Vishwanath, 2012). Initial therapy aims to preserve 
borderline tissue, reduce oedema, improve local host defences and promote wound closure. Usual 
care includes antibiotics, debridement and respiratory care. 
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As mentioned, hyper-oxygenation increases vasoconstriction of vessels and therefore decreases 
oedema enhances the formation of collagen and angiogenesis (Zamboni et al, 1993). Despite a 
number of studies that support the use of HBOT in thermal burns, recent reviews report insufficient 
level of evidence to provide clear practice guidelines (Villanueva et al, 2009; Cianci et al, 2013). 
 
It has been suggested that HBOT is commenced as soon as  possible following injury and with three 
sessions within 24hrs. Treatment has been recommended twice daily with 90 minutes per 
treatment at 2.0 - 2.4 ATA (Hampson, 1990; Gesell, 2008; Cianci et al, 2013). 
 
 
Idiopathic Sudden Sensorineural Hearing Loss 
 
Idiopathic sudden sensorineural hearing loss (ISSHL) is an hearing impairment with sensorineural 
hearing loss greater than 30 dB in three sequential frequencies occurring over three days (Hughes, 
1996). The exact cause of ISSHL is unknown and it has been suggested that a number of pathogens 
maybe involved including, viral infections, inner ear membrane rupture, trauma, toxins, 
autoimmune disease and vascular occlusion (Thurmond & Amedee, 1998). 
 
A number of different treatments have been proposed, without large randomised controls to 
support their use. Administration of steroids has been one of the most frequently utilised treatment 
approaches, although studies to support its use are poor (Labus et al, 2010). ISSHL was added to the 
UHMS list of indications for HBOT therapy, approved by the UHMS Board of Directors on October 
8th 2011 (Nikitopoulou & Papalimperi, 2015).  
 
The use of HBOT has been proposed because it has been suggested that hearing loss may be the 
result of hypoxia or other inflammatory processes leading to ischeamic changes effecting the 
cochlea apparatus function (Mazurek et al, 2006). In the event of reduced oxygenation to structures 
within the cochlea, the oxygen concentration would be restored using HBOT (Pezzoli et al, 2015).  
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Recommended treatment parameters for the use of HBOT for ISSHL are 100% oxygen at 2.0 - 2.5 
ATA for 90 mins per day for up to 10 - 20 sessions dependent on the duration of symptoms and the 
severity (Hampson, 1999; Gesell, 2008)  
 
 
Summary of the uses of HBOT  
 
The use of HBOT to treat a number of medical has been recommended despite the varied evidence 
base. Of the 14 conditions accepted by FDA and the UHMS the evidence for air embolism and 
decompression is well established and stronger than the other 12 conditions. Despite a number of 
other suggested indications for HBOT, including sports injuries, fracture healing and bone grafting, 
head injuries, spinal cord injuries, the evidence remains, albeit extensive, weak, lacking in 
randomised controlled trails  and largely anecdotal. In order to establish the efficacy in other 
conditions further research is required.  
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The Safety of HBOT  
 
Although considered a relatively safe treatment, with rare complications, due to the hyperoxic 
effect and increased pressure involved, HBOT does bring some risks (Leach, 1998). Although severe 
side effects and life threatening cases are rare, HBOT cannot be considered an entirely safe clinical 
intervention (Bennett at al, 2012).  
One of the most common side effects lasting anywhere from weeks up to months following HBOT is 
reversible myopia, which occurs as a result of the toxic oxygen on the lens of the eye, (Leach et al, 
1998). Other reported general features include claustrophobia, fatigue, vomiting and headache. 
Claustrophobia is more commonly seen in mono-place (single person) chambers. Mono-place 
chambers also carry an increased fire risk, which is the most common fatal complication, as the 
whole chamber contains hyperbaric oxygen, which is not flammable or explosive but it would 
support combustion (Leach, 1998; Orsted & Poulson, 2012). 
Other common and less severe problems include patient difficulty with pressure equalisation within 
the middle ear and sinus barotrauma (injury caused by a change in air pressure affecting typically 
the ear). To minimise barotrauma a reduced rate of compression / decompression is recommended. 
To further reduce the risk of barotrauma and the discomfort associated with it, an explanation on 
effective ear clearance should be provided (Fitzpatrick et al, 1999).  
The increase in oxygen partial pressure may affect the glucose levels of diabetic patients.  
A more serious complaint is pulmonary oxygen toxicity, which may result after continuously 
breathing 100% oxygen at sea level (1 ATA) over approximately 36 hours. Whereas when the 
pressure is increased to 2 ATA oxygen toxicity ensues after 6 hours (Kindwall, 2002).  
With time periods reaching 3 hours and with pressures up to 3 ATA, oxygen toxicity no longer 
becomes the main problem as periods of time spent at these parameters is likely to result in seizure 
(Kindwall, 2002).  
Repeated HBOT treatments may result in drop in pulmonary function (Leach et al, 1998). However, 
it has been confirmed that oxygen tissue toxicity may be prevented by introducing air breaks 
approximately every 30 minutes to prevent the formation of free oxygen radicals (Leach et al, 1998; 
Kindwall, 2002). However, if the length of treatment is no longer than 120 minutes and pressure 
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does not exceed of 3 ATA and with the number of individual sessions no greater than 30 treatment 
is considered absolutely safe (Leach et al, 1998). 
A number of studies have demonstrated that HBOT does not increase the reoccurrence nor does it 
promote the growth of tumours (Moen & Stuhr, 2012). A recent Cochrane review carried out to 
assess the benefits and harms of radiotherapy while breathing HBO found evidence that the control 
of tumours is improved (Bennett et al, 2012).  
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Contraindications for HBOT  
 
 
Absolute Contraindications (Sharkey, 2000) 
 
 
• Untreated tension pneumothorax - developing tension pneumothorax is highly probable 
with compression and decompression during HBOT (Bhutani & Vishwanath, 2012). 
• Certain Medications - Some medications have been observed to become toxic during HBOT: 
• Chemotherapeutic drugs 
• Doxorubicin and Cisplatin 
• Bacterial infection drugs; 
• Mafenide acetate 
• Treatment of alcoholism, Disulfiram (Smith, 2011) 
 
Relative Contraindications: 
 
 Upper respiratory tract infections 
 Emphysema with carbon dioxide retentions 
 Asymptomatic pulmonary lesions which are seen on X-ray 
 History of thoracic or ear surgery 
 Uncontrolled Hypothermia 
 Pregnancy  
 Claustrophobia    
 Seizure disorder  
 Presence of a cardiac pacemaker  
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 Side Effects: 
 
 Middle ear/pulmonary barotrauma 
 Vomiting 
 Cataract 
 Fatigue 
 Claustrophobia (Considered a contraindication but on occasions can occur during treatment 
and so can be regarded as a side effect)  
 Oxygen toxicity: 
o Pulmonary 
o Central Nervous system – rare occurrence of seizures 
 Hypoglycaemia 
 Thrombocytopenia 
 Respiratory failure 
 Fire hazard 
 Headache 
 Disease as a result of rapid decompression 
 Diabetes – sugar levels /cardiac history - attention given due to the vasoconstrictive effect of 
HBOT 
 
Although the risk is minimal and usually reversible when using HBOT, the complications or 
contraindications have not been identified when used in clinical trials. A Cochrane review (Kranke et 
al., 2015) to assess the benefits and harms of adjunctive HBOT for treating chronic ulcers of the 
lower limb reported that of the five studies reviewed, three failed to report on the potential hazards 
or detrimental outcomes and two studies clearly stated that hyperbaric oxygen therapy carried no 
risks or complications.  
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In order to prevent harmful incidences associated with HBOT it is advised that patients with known 
complications should be identified to allow for the rate of compression and decompression to be 
altered accordingly.  
 
A summary of the Safety of HBOT   
 
The use of HBOT can be determined as safe, however, fire is always a possible hazard, but so long as 
extensive precautions are made, prevention is ensured. When procedures and protocols are strictly 
adhered to by the participants involved, potential risks are likely to be avoided. 
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Soft Tissue Healing and HBOT 
 
 
Method: 
 
Electronic searches of the following databases were undertaken: 
 The Cochrane, Joint and Muscle Trauma Group Specialised Register (to September 2015) 
 AMED (Allied & Complimentary Medicine. 1985 to September 2010),  
 OVID MEDLINE (1946 to September Week 4),  
 SPORTDiscus (1980 - present) 
 Searched Reference lists of articles.   
Key words used: 
Soft tissue injuries, Humans, Sports injuries, athletic injuries, arm, leg, ligament, tendon, muscle, 
Hyperbaric oxygenation, oxygen, hyperbaric, chamber, monoplace, multiplace, randomised 
controlled trial, controlled clinical trial, controlled study, prospective study double blinded, single 
blinded.  
All randomised and quasi-randomised controlled trials that compared HBOT with no HBOT (sham or 
no treatment) were included.  
Patients with closed injuries to ligament, tendon or muscle tissue with the inclusion of DOMS.  
No restrictions on gender or age were made.  
Any standard HBOT treatment regimen using pressures 1.5 ATA - 3 ATA for 30 minutes to 60 minute 
individual treatment periods for promoting soft tissue or bone injury was accepted.     
The search revealed 9 small trials, identified in the tables below. Of the nine trials, 7 examined the 
effect of HBOT on DOMS. Two of the trials, Staples 1999a and Staples 1999b, represent the first and 
second phase of the same study. The remaining 2 trials compared HBOT versus sham therapy on 
closed soft tissue injuries that included medial collateral knee ligament and ankle sprain.  
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A Cochrane systematic review was identified in the search. This study was initially conducted in 
2005, with a new search for studies and content updated in 2010, although no changes to 
conclusions were made (Bennett et al, 2010).  
 
The review describes the use and parameters of HBOT. The safety of HBOT will also be reviewed 
with particular focus on known side effects, contraindications to its use and the precautions 
required to ensure the safe use of HBOT. A review of HBOT for soft tissue injures, including DOMS, 
and fracture healing will be included. The article will concluded with recommendations for the use 
of HBOT and the implications for practice and future research.  
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FIGURE 1 SAFETY CONSIDERATIONS IN HBOT STUDIES FOR SOFT TISSUE INJURY 
Author date / Methods Pathology Side effects 
Experienced 
Precautions 
[Who should not have HBOT] 
Recommendations 
[When not to use it] 
Babul, 2003  
Randomised. patient and 
assessor blind  
 
 
Acute soft tissue injury - 
provocative exercise of non-
dominant quadriceps muscle  
Non reported  Individuals who had experienced quadriceps DOMS in 3 
months prior to study or who had a past history of severe 
joint injury, arthritis or other chronic illness were 
excluded. Subjects taking analgesics or prescription drugs 
were also excluded  
Not indicated 
Borromeo, 1997  
Randomised, patient and 
assessor blind. intention to 
treat analysis  
Lateral ankle sprain within 
72 hours  
Increased pressure 
exposure or hyperbaric 
oxygen caused no 
adverse effects.  
Contra-indications to HBOT  Subjects were excluded with severe asthma, active 
allergies, pulmonary disease, epilepsy, upper 
respiratory infections and pregnant.  
Germain, 2003  
Randomised, not blinded  
Deliberately provocative 
exercise of the quadriceps 
muscle  
   
Harrison, 2001  
Randomised, patient partial 
blinding  
Deliberately provocative 
exercise of elbow flexors  
Non reported  Health issues such as heart disease, diabetes and smoking 
that would exclude subjects from the study were 
evaluated using a physical health questionnaire  
Health issues such as heart disease, diabetes and 
smoking that would exclude subjects from the study 
were evaluated using a physical health questionnaire  
Mekjavic, 2000   
Randomised, patient and 
statistician blind  
Deliberately provocative 
exercise of elbow flexors  
Non reported  Non reported  Non reported  
Soolsma, 1996  
Randomised, method not 
specified. Participant and 
assessor blind.  
Grade II injury to the medial 
collateral ligament of the 
knee - presenting to an 
orthopaedic surgeon within 
72 hours of injury  
Non reported  Non reported  Non reported  
Staples 1999a  
Randomised, participant 
blind and probably assessor 
blind  
Deliberately provocative 
exercise of the non-
dominant quadriceps muscle  
Non reported  Recent respiratory tract infection / confinement anxiety  A physician assessed and excluded subjects 
considered incompatible to HBOT including: idiopathic 
lung cyst, pneumothorax, hyperinflation, any other 
lung problem, unresolved upper respiratory tract 
infection and if suffering a fever at the time of HBOT 
exposure.  
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Staples 1999b  
Randomised, participant and 
probably assessor blind  
Deliberately provocative 
exercise of the non-
dominant quadriceps muscle  
Non reported   A physician assessed and excluded subjects 
considered incompatible to HBOT including: idiopathic 
lung cyst, pneumothorax, hyperinflation, any other 
lung problem, unresolved upper respiratory tract 
infection and if suffering a fever at the time of HBOT 
exposure.  
Webster, 2002  
Randomised,  
patients and assessor blind  
Deliberately provocative 
exercise of the 
gastrocnemius muscle  
Non reported  Inspection of subject eardrums for pathology took place 
before and after each hyperbaric treatment.  
A physician examined the subjects to rule out any 
contraindications to hyperbaric therapy.  
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FIGURE 2 PICO TABLE FOR SOFT TISSUE STUDIES 
Author date N= Population Intervention comparator Outcomes Results 
Webster, 2002  12 healthy young 
male volunteers  
100% oxygen at 2.5 ATA 
for 60 minutes at 3, 24, 
and 48 hours post injury  
Sham HBOT at 1.3 ATA on 
air on the same schedule  
PAIN SCORE  
Descriptor differential scale expressed as 
percentage changes compared to maximal 
pain. (data not used due to difficulties in 
interpretation  
STRENGTH  
change from baseline as maximal 
eccentric torque expressed as a 
percentage  
SWELLING 
percent change in cross-sectional area of 
medial gastrocnemius   
The study found some evidence of a faster 
recovery of isometric torque and the 
reduction of pain and unpleasantness from 
days 2 to 5 post muscle damage using HBOT. 
Germain, 2003  16 16 Healthy 
volunteers (10 
females) 
95% oxygen at 2.5 ATA for 
100 minutes at 1 and 6 
hours post injury, then 1 
treatment the next day 
and 2 treatments on the 
next day separated by 6 
hours.  
nil specific therapy  PAIN SCORE: visual analogue scale (0-10) 
STRENGTH 
change from baseline - maximum 
eccentric torque in Nm 
SWELLING 
tape measurement  
The two groups showed no significant 
differences. 
Babul, 2003  16 healthy female 
volunteers  
HBOT  
100% oxygen at 2.0 ATA 
for 60 minutes at 4, 24, 48 
and 72 post-injury  
CONTROL 
Sham HBOT at 1.2 ATA on 
air on the same schedule  
PAIN SCORE: visual analogue scale (0-10) 
 
STRENGTH 
change from baseline - maximum 
eccentric torque in Nm 
 
SWELLING 
tape measurement  
Administration of HBOT after eccentric 
exercise demonstrated no effect on the 
elevation of the various signs and symptoms 
associated with muscle injury or DOMS. 
Variables investigated demonstrated no 
statistical significance  
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Mekjavic, 2000 24 healthy male 
volunteers  
HBOT  
standard exercise protocol 
followed by 7 sessions in 
100% oxygen for 60 
minutes daily at 2.5 ATA  
CONTROL 
standard exercise protocol 
followed by 10 sessions in 
a sham hyperbaric 
treatment (2.5 ATA, 8% 
oxygen for 60 minutes) 
once daily  
PAIN SCORE  
visual analogue scale (0-10)  
 
STRENGTH  
Change from baseline as maximal 
isometric strength in kilopascals before 
and for 10 days following exercise. 
measured by blinded researcher  
 
SWELLING  
arm circumference  (cm) 
HBOT is not considered effective as a 
treatment for DOMS  
Soolsma, 1996 19 19 participants (5 
females)  
HBOT  
within 96 hours of injury - 
at 2.0 ATA on 100% 
oxygen for 60 minutes, 10 
sessions over 2 weeks  
 
Regular icing, stretching 
and strengthening exercise 
rehabilitation program 
Sham HBOT exposure to 
1.2 ATA breathing air on 
the same schedule  
 
Regular icing, stretching 
and strengthening exercise 
rehabilitation program 
SUBJECTIVE RECOVERY INDEX  
questionnaire  
 
PAIN SCORE  
visual analogue scale (0-10) 
 
RANGE OF MOTION  
 
ONE-LEGGED HOP TEST  
 
SWELLING  
measured with tape and volume by 
blinded researcher from MRI  
FIGURE OF EIGHT PERFORMANCE TEST  
time taken to complete a standard course 
- measured by blinded researcher  
 Patients treated with HBOT displayed a more 
rapid decrease in oedema volume, less 
muscle wasting, greater improvements in 
maximum flexion and greater range of 
movement. However, numbers allocated to 
each arm of this study were not reported 
Staples 1999a 49 healthy male 
volunteers  
HBOT (2 groups) 
 
100% oxygen at 2.0 ATA 
for 1 hour at 0, 24, and 48 
hours after exercise, 
followed by 2 sham 
treatments at 72 and 96 
hours  
 
Sham at 0 and 24 hours, 
followed by HBOT at 48, 
72 and 96 hours  
CONTROL  
(2 groups) 
 
No specific intervention  
 
Sham HBOT by exposure 
to 1.2 ATA breathing air at 
0, 24, 48, 72 and 96 hours 
for one hour on each 
occasion  
PAIN SCORE  
Visual analogue: 
 (0-10) 
 
STRENGTH  
change from baseline as maximal 
eccentric torque measured in Nm  
No changes in pain were reported. Following 
the treatment it was suggested that HBOT 
may aid recovery from DOMS following 
eccentric quads exercise. A significant 
eccentric torque recovery was noticed in 
phase 1 and the 5 day treatment also showed 
a significant difference in phase 2. 
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Harrison, 2001  21 Healthy male 
volunteers  
HBOT (2 Groups) 
Immediate HBOT: 100% 02 
at 2.5 ATA for 100 mins. 
Treatments immediately 
post-injury and 24, 48, 72 
and 96 hours.  
 
Delayed HBOT. Immediate 
sham (on air at minimal 
pressure) then the same 
schedule as above.  
No specific therapy  PAIN SCORE  
verbally anchored 10 point scale  
 
STRENGTH  
change from baseline as maximum 
strength measured in kilograms  
 
SWELLING  
cross-sectional area estimated from MRI 
in mm2 
The lack of significant differences suggest 
HBOT was not effective in treatment of 
exercise induced muscle injury  
Staples, 1999b 30 Healthy male 
volunteers  
HBOT  
(2 groups)  
 
100% oxygen at 2.0 ATA 
for 1 hour at 0, 24, 48 
hours after exercise, 
followed by two sham 
treatments at 72 and 96 
hours. 
 
Same HBOT on five 
occasions at 0, 24, 48, 72 
and 96 hours  
CONTROL 
Sham HBOT by exposure 
to 1.2 ATA breathing air at 
0, 24, 48, 72, and 96 hours  
PAIN SCORE  
Visual analogue (0-10) 
 
STRENGTH  
change from baseline as maximal 
eccentric torque measured in Nm  
No changes in pain were reported. Following 
the treatment it was suggested that HBOT 
may aid recovery from DOMS following 
eccentric quads exercise. A significant 
eccentric torque recovery was noticed in 
phase 1 and the 5 day treatment also showed 
a significant difference in phase 2. 
Borromeo, 1997 32 32 adults (11 
females) 
HBOT at 2.0 ATA on 100% 
oxygen for 90 minutes.  
 
Posterior splint, crutches, 
NSAID, AROM exercise, 
ankle stirrup   
Sham HBOT exposure to 
1.1 ATA breathing air for 
90 minutes  
HEALED TO FINAL FOLLOW UP 
TIME TO NO FURTHER SYMPTOMS  
FUNCTIONAL SCORE  
 
PAIN SCORE: 
VAS (0-10) 
 
SWELLING: 
water displacement volumeter  
No significant differences in oedema, pain, 
passive/active ROM or recovery time were 
found. However, an improvement in joint 
function was demonstrated in the HBOT 
group (95% CI 0.15 - 2.65; p=0.03). 
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FIGURE 3 USES / PARAMETERS FOR HBOT IN CLOSED SOFT TISSUE 
Author / date Pathology %O2 Atmospheres Absolute Duration N of sessions 
Babul, 2003 Provocative of non-dominant 
quadriceps muscle  
100% 2.0 ATA  60 minutes  4 sessions  
4, 24, 48 and 72 hours post injury  
Borromeo, 1997 Lateral ankle sprain within 72 
hours  
100% 2.0 ATA  90 minutes  3 sessions over 7 days  
Germain, 2003  Deliberately provocative 
exercise of the quadriceps 
muscle  
95% 2.5 ATA  100 minutes  5 sessions at 1 and 6 hours post injury, then 1 treatment 
the next day and 2 treatments on the next day 
separated by 6 hours  
Harrison, 2001  Deliberately provocative 
exercise of elbow flexors 
100% 2.5 ATA  100 minutes  5 sessions post injury and 24, 48, 72 and 96 hours  
Mekjavic, 2000 Deliberately provocative 
exercise of elbow flexors  
100% 2.5 ATA  60 minutes  7 daily sessions  
Soolsma, 1996  Grade II injury to the medial 
collateral ligament of the knee - 
presenting to an orthopaedic 
surgeon within 72 hours of 
injury  
100% 2.0 ATA  60 minutes  10 sessions over 2 weeks  
Staples 1999a Deliberately provocative 
exercise of the non-dominant 
quadriceps muscle  
100% 2.0 ATA  60 minutes  3 sessions at 0, 24 and 48 hours  
Staples 1999b  Deliberately provocative 
exercise of the non-dominant 
quadriceps muscle  
100% 2.0 ATA 60 minutes  2 groups  
at 0, 24, 48hours after exercise, followed by two sham 
treatments at 72 and 96 hours  
0, 24, 48, 72, and 96 hours  
Webster, 2002 Underwent deliberately 
provocative exercise of the 
gastrocnemius muscle  
100% 2.5 ATA 60 minutes  3 sessions  
 
3, 24 and 48 hours post injury  
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A Review of the Use of HBOT for Soft Tissue Repair 
 
Borromeo et al., (1997) 
A randomised, double-blinded study was carried out by Borromeo et al, (1997), to determine 
the effects of HBOT in the rehabilitation process following ankle sprains. The study observed a 
total of 32 patients allocated between HBOT, receiving 100% oxygen at 2 ATA for 90 mins for 
the first session and 60mins for the further two sessions. The placebo group received ambient 
air at 1.1 ATA for the same time periods and number of sessions. Both groups received three 
sessions over 7 days and the same standardised treatment. No significant differences in 
oedema, pain, passive/active ROM or recovery time were found. However, an improvement in 
joint function was demonstrated in the HBOT group (95% CI 0.15 - 2.65; p=0.03). No 
explanation of the randomisation procedure was carried out which may question the bias of 
the study. No patients were lost to follow up. From initial injury there was a reported 34 hour 
delay before the patient received treatment which may have influenced the potential influence 
of HBOT in this study. No complications were reported in this study. 
 
Soolsma et al, (1996)  
Soolsma et al, (1996), examined the use of HBOT to determine whether it will influence the rate 
of recovery from a grade II medial collateral ligament injury of the knee. They carried out a 
double blinded study with 19 patients, presenting within 72 hours of injury, of whom 14 
finished the clinical assessment. The MRI investigation was completed by only 9 patients. The 
number of patients allocated to each group was not reported. The HBOT group received 100% 
oxygen at 2 ATA for 1 hour and the control group received room air at 1.2 ATA for 1 hour both 
treatments over 10 days. Patients treated with HBOT displayed a more rapid decrease in 
oedema volume, less muscle wasting, greater improvements in maximum flexion and greater 
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range of movement. However, numbers allocated to each arm of this study were not reported. 
No explanation of randomisation procedure was given.  
 
Staples et al, (1999a) and Staples et al, (1999b) reported in same study: phase 1 and phase 2  
Using a randomised, controlled, double-blind, prospective study of 66 untrained men, Staples 
et al, (1999), aimed to determine whether recovery from DOMS was enhanced using 
intermittent exposures of HBOT. Following exercise to produce muscle soreness the subjects 
were randomised to one of four groups; control, HBOT, delayed HBOT and sham, over a period 
of 5 days for the first phase. In the second phase there were three groups consisting of 5 days 
of treatment, 3 days of treatment and sham treatment. The HBOT group received 100% oxygen 
at 2 ATA for 1 hour and the sham received 21% oxygen at 1.2 ATA for 1 hour. No changes in 
pain were reported. Following the treatment it was suggested that HBOT may aid recovery 
from DOMS following eccentric quads exercise. A significant eccentric torque recovery was 
noticed in phase 1 and the 5 day treatment also showed a significant difference in phase 2. The 
study reported subject randomisation but failed to offer an explanation of the procedure used. 
The protocol for this study was complex and the design wasn't fully clear; 4 subjects were 
rejected after they displayed an increase in strength after the exercise protocol, 13 subjects 
were not reported on and the study was not completed by 9 subjects.  
 
Mekjavic et al, (2000) 
In this study of 24 healthy males with induced DOMS, the participants were randomised to the 
HBOT group or the placebo group.  No difference in muscle strength recovery or pain was 
reported after HBOT. The parameters used were 100% oxygen at 2.5 ATA for the HBOT group 
and 8% oxygen at 2.5 ATA, both lasting for 1 hour for a period of 7 days.  There were no reports 
of participants lost to follow up or disruption of the protocol. As with a number of other studies 
this one failed to identify procedure of subject randomisation.  
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Harrison et al, (2001) 
The effect of HBOT after inducing DOMS in 21 healthy males was studied comparing 3 groups; 
immediate HBOT, delayed HBOT and control. The HBOT groups received 100% oxygen at 2.5 
ATA for 100mins, consisting of 3x30min in addition to two 5 min periods of 21.93% oxygen. 
Treatment for the immediate HBOT and control started at 2hrs, delayed group was given sham 
until HBOT commenced at 24hrs and they all received treatment daily for 4 days. The control 
group did not receive any specific treatment. The randomisation procedure was not identified.  
Webster et al, (2002) 
This study looked at the use of HBOT as a treatment following exercise induced muscle damage. 
The study involved concentric and eccentric exercise of the gastrocnemius in 12 healthy male 
volunteers. The HBOT group received 100% oxygen at 2.5 ATA and the sham group received 
atmospheric air at 1.3 ATA. Both groups received 3 sessions of 60 minutes at 2-4 hours at 24 
hours and at 48 hours. The study found some evidence of a faster recovery of isometric torque 
and the reduction of pain and unpleasantness from days 2 to 5 post muscle damage using 
HBOT. Despite no losses to follow up the study sample was small.  
 
Babul et al, 2003  
Babul et al. (2003), conducted a small randomised, double blind study which included 16 female 
participants with the aim to determine whether HBOT aided the rate of recovery from exercise 
induced injury in the quadriceps muscle. The HBOT group received 100% oxygen at 2.0 ATA and 
the sham received 21% oxygen at 1.2 ATA, both for 60 minutes. Each received treatment at 4, 
24, 48, 72 hours post injury. Reported data only included differences between HBOT and 
control instead of outcomes in each group.  
Due to lack of data this study was not included in the Bennett et al, (2010) meta-analysis. 
 35 
Germain et al, (2003) 
This study randomly assigned 16 subjects (10 female and 6 male) into two un-blinded groups. 
The study aimed to determine whether HBOT accelerated the recovery of exercise induced 
muscle injury. The HBOT group received 95% oxygen at 2.5 ATA for 100 minutes for a total of 
five sessions and the control didn't receive any treatment. The two groups showed no 
significant differences. This again was a small sample from which one of the sample was lost to 
follow up and was not reported on.   
Due to lack of data this study was not included in the Bennett et al, (2010) meta-analysis. 
 
A summary of the Use of HBOT for Soft Tissue Repair 
 
Of the studies identified in the search, five (Webster et al, 2002; Soolsma et al, 1996; Staples et 
al 1999a and 1999b; Borromeo et al, 1997) identified a potential benefit using HBOT. The 
remaining four studies suggested no significant differences (Germain et al, 2003; Babul et al, 
2003; Mekjavic et al, 2000; Harrison et al, 2001).  
Four studies suggested that HBOT may hinder DOMS recovery (Staples 1999a and 1999b; 
Mekjavic et al, 2000; Harrison et al, 2001). However, the identified studies were generally of 
poor methodological quality, with 2 studies failing to provide the number of each group. The 
majority of studies suggested randomisation but did not identify the procedure used, two 
studies (Babul et al, 2003; Germain, 2003) provided very limited data and one study had a 
number of aspects that remained unclear (Soolsma et al, 1996). 
The lack of available randomised controlled trials on application of HBOT for the treatment of 
delayed onset muscle soreness and closed soft tissue injury make it difficult to evaluate its 
efficacy. In addition to this the studies often fail to include relevant control groups which may 
help to determine whether the effect is due to solely an increase in pressure or to a 
combination of pressure and the presence of oxygen. Optimum pressure, frequency and 
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duration of treatments should be considered in future trials. In order to determine the 
effectiveness of HBOT further RCTs with larger samples are required. 
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Critical appraisal of Bennett et al, (2010), Hyperbaric oxygen 
therapy for delayed onset of muscle soreness and closed soft 
tissue injury: A Cochrane Review 
 
The Bennett et al, (2010), systematic review included nine trials on HBOT for delayed onset 
muscle soreness and closed soft tissue injury. We used the Critical Appraisal Skills Programme 
(CASP) checklist to appraise this review to enable the appraisers to make sound judgements on 
its trustworthiness and relevance. The CASP checklist is used to appraise the research evidence 
in practice, aid personal and professional decision making, and to help develop policy and 
guidelines. The methodological quality of the review was evaluated to identify signs of bias to 
help determine the validity of the review. In particular aim to identify an unbiased inclusion / 
exclusion criteria, whether the search for studies was detailed, exhaustive and multifaceted. 
Whether the studies included were of high methodological quality and reproducible. In 
understanding the quality of the review, the conclusions can be considered to be trustworthy. 
 
CASP Checklist 
1. Did the review address a clearly focused question? 
Yes.  
The objective was to assess the benefits and harms of HBOT for treating soft tissue injury, 
including delayed onset of muscle soreness (DOMS).  
The objective of the study was clearly stated, in aiming to assess the evidence for the use of HBOT to 
treat soft tissue injuries including DOMS. With the main aim to determine whether HBOT safely 
improves and speeds up functional outcome after injury.  
 
2. Did the authors look for the right papers? 
 38 
Yes.  
The authors used / considered any randomised or quasi-randomised clinical trials that 
compared HBOT with no HBOT.  
The authors restricted the review to acute closed injuries involving muscle, ligament and 
tendon, and where the mechanism is unaccustomed use, trauma from a direct blow, strain or 
overuse injury.  
Trials comparing HBOT with no treatment or sham alone and using alternative therapies as the 
comparator were considered.  
Population included patients with DOMS following exercise or patients with closed injury to 
ligament, tendon or muscle.  
 
3. Do you think all the important, relevant studies were included? 
Yes.  
The authors searched:  
• The Cochrane bone, joint and muscle trauma group specialised register (to Feb 2010), 
the Cochrane Central Register of Controlled Trials, MEDLINE (1950 to February 2010), 
EMBASE (1980 to 2010 week 07), CINAHL (1982 to October 2008).  
• An additional database that had been developed in the authors hyperbaric facility and 
reference lists of articles.  
In addition, the authors also hand searched relevant journals and textbooks and made contact 
with researchers in the field.   
Authors of relevant studies were also contacted to request details of ongoing or unpublished 
investigations.   
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One author was responsible for hand searching and identification of eligible studies, whilst the 
other three authors examined the electronic search results and identified potentially eligible 
studies. 
 All languages were considered. 
 
4. Did the review’s authors do enough to assess the quality of the included studies? 
Yes.  
The review stated that the four authors evaluated study quality and extracted data.  
Authors of the included trials were contacted to provide missing data and information 
regarding the trial.  
Individual patient data was sought to enable comparisons of mean values across studies.  
To perform intention to treat analysis, all data extracted reflected the original allocation groups 
where possible.  
Losses to follow up were identified where possible.  
For the majority of trials the authors estimated means and standard deviations from graphs 
presented without tabulated data in the trial reports.  
The Authors used a modified method previously outlined by Schultz et al (1995) to assess the 
study quality. They assessed the adequacy of randomisation, adequacy of allocation 
concealment, completeness of outcome data and the level of masking.  
The Authors also made comments on issues they identified regarding the study process. The 
Authors failed to mention what type of critical appraisal tool they used.  
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Sensitivity analysis, based on the Schultz et al (1995) score was performed to investigate the 
effects of study quality and the missing data. This allowed the analysis of more than one set of 
assumptions to investigate any discrepancies.  
The authors looked at best and worst case scenarios. Best = none of the originally enrolled 
participants missing from the primary analysis in the treatment group had the negative 
outcome of interest whilst all those missing from the control group did. The reverse of this 
outcome was used as the worst case scenario. 
The quality of the studies’ methodology was assessed and considered fair to high. The 
randomisation procedure was not described in seven of the 9 studies.   
 
5. If the results of the review have been combined, was it reasonable to do so? 
Yes.  
The results of the different injuries were combined. However, the different injury categories 
were analysed separately. The different categories separately analysed were tendon / ligament 
injury or DOMS. Considering the differing injury type it could be considered reasonable to do 
so.  
In addition, subgroup analysis where appropriate data was available was considered of the 
following: injury entry grade or severity, type of injury/location, oxygen received , ATA, time, 
length of treatment course, type of comparative treatment, age (adults versus children), nature 
of activity undertaken 
 
6. What are the overall results of the review? 
Insufficient evidence from comparisons tested within randomised controlled trials to establish 
the effects of HBOT on ankle sprain or acute knee ligament injury.  
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The studies showing significant improvement:  
 For ankle sprains, Borromeo (1997), reported a significant improvement on functional 
assessment in HBOT compared to control. However, the authors suggest that the scale 
has not been validated and therefore the results should be interpreted cautiously. Pain 
scores were also higher for the HBOT group, although there was no significant 
difference after the final treatment session. The mean scores were statistically 
significantly better in the HBOT group after 10 treatments, but not after 5 treatments, 
for grade II medial collateral injury (Soolsma, 1996). However, a number of features in 
this study remain unclear; the number of participants allocated to each arm are 
unknown. 
 No evidence suggests that HBOT improves speed of recovery from DOMS treatments 
(Webster, 2002; Harrison, 2001; Mekjavic, 2000; Staples 1999b; Staples, 1999a). 
 There was some evidence that in treating muscle soreness, HBOT may hinder recovery, 
as there was a statistical significance in pain scores at 48 hours (Harrison, 2001; 
Mekjavic, 2000; Staples, 1999b; Staples, 1999a). However, no statistical difference was 
shown at the end of treatment.  
 
7. How precise are the results? 
Different injury categories; tendon / ligament injury / DOMS, were analysed separately. The 
majority of the results displayed on the forest plots show cross the line of no effect. This would 
support that there was no significant difference between treatments. However, these results 
may be as a result of the sample size being too small to be confident where the true result lies.  
Ankle function displayed 95%CI of (0.15 - 2.65) suggesting statistical significance. However, as 
previously stated the authors report that the scale has not been validated.  
 42 
The results of subgroups for HBOT versus control for induced DOMS displays that the observed 
difference is not statistically significant, because from the majority of results the 95% CI do not 
cross the relative risk of 1. With only HBOT pain scores of statistical significance demonstrated 
at 48hrs and 72hrs. 
 
8. Can the results be applied to the local population?  
There was only a small number of studies with only one study for ankle sprain and one for 
acute knee ligament injury. It is difficult to draw conclusion from a small number of 
participants.  
Two trials evaluated HBOT for soft tissue injury presenting within 72 hours of injury. There was 
no mention of subject age or gender. The other seven trials included unconditioned young 
adults, studies enrolling females only, males only and a mix of males and females.  
Participants in the studies included in the review do not accurately reflect a population of 
conditioned male professional footballers. However, they would not be sufficiently different 
from our population to cause concern. 
 
 
9. Were all important outcomes considered? 
From the studies review the following outcomes were considered:  
Primary outcomes:  
 Proportion returning to pre-injury activity  
 Time to reach full function following injury  
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 Persisting pain following injury  
Secondary outcomes: 
 Functional assessment scores  
 Pain and swelling  
 Strength  
 Complications of therapy   
 
Bennett et al, (2010) mentioned the following outcomes but failed to consider any in the final 
outcomes:  
• Creatine Kinase has been previously studied in relation to muscle damage due to 
strenuous exercise. Two of the later studies (Babul, 2003; Germain, 2013; Harrison, 
2001) include this in their outcomes.  
 
Other outcomes mentioned but not considered in the review outcomes are: 
• Serum malondialdehyde (This reactive species occurs naturally and is a marker for 
oxidative stress) (Babul, 2003)  
• MRI (Babul, 2003., Harrison, 2001; Soolsma, 1996; Webster, 2002)  
• Magnetic resonance spectroscopy (Webster, 2002)  
• Ratio of figure of 8 to straight running ability (Soolsma, 1996) 
• Transcutaneous oxygen measurement (Harrison 2001; Mekjavic, 2000)  
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From this, it might be suggested that Bennett et al, (2010) omitted some important outcome 
measures.  
 
10. Are the benefits worth the harm and costs?  
The recommendation is that HBOT is safe, although there needs to be further studies carried 
out to support its use. Nothing is mentioned in the paper regarding costs, therefore difficult to 
report on the cost effectiveness of HBOT.   
 
A Summary of the Review of Bennet et al, (2010) 
 
Following appraisal of the review by Bennett et al. (2010), using the CASP tool, it can be 
concluded that the review is of good methodological quality. CASP identified an unbiased 
inclusion / exclusion criteria and that the search was detailed, exhaustive and multifaceted. 
However, in agreement of our view the included studies were not of high methodological 
quality. The study by Babul (2003) was identified as higher in quality than the other studies; 
however, this was omitted from the review along with the Germain et al., (2003) study due to 
the lack of data.  The review concluded that the use of HBOT for closed soft tissue injury and 
delayed onset muscle soreness cannot be justified from the findings.  
  
 45 
HBOT as a Treatment for Fractures 
 
This section describes a review of the literature to determine whether HBOT is a suitable 
intervention for the treatment of fractures. 
Electronic searches of the following databases were undertaken: 
 The Cochrane, Joint and Muscle Trauma Group Specialised Register (to September 
2015) 
 AMED (Allied & Complimentary Medicine. 1985 to September 2010)  
 OVID MEDLINE (1946 to September Week 4)  
 SPORTDiscus (1980 - present) 
 Searched Reference lists of articles  
 
Key words used: 
Fractures, bone, fixation, fracture healing, non-union, delayed union  Hyperbaric oxygenation, 
oxygen, hyperbaric, chamber, monoplace, multiplace, Randomised controlled trial, controlled 
clinical trial, controlled study, prospective study double blinded, single blinded.  
All randomised and quasi-randomised controlled trials that compared HBOT with no HBOT 
(sham or no treatment) were included.  
Patients with bone fracture, delayed, or non-union of bony fractures. 
No restrictions on gender or age were made.  
Any standard HBOT treatment regimen using pressures 1.5 ATA - 3 ATA for 30 minutes to 60 
minute individual treatment periods for promoting fracture healing or delayed or non -union 
was accepted. 
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The search revealed no randomised controlled trials with appropriate outcomes to support the 
use of HBOT for bone fracture, delayed or non-union of bony fractures. 3 ongoing trials were 
identified registered trials in progress: One being a multi centred international non-blinded 
randomised trial: ‘Hyperbaric Oxygen for Lower Limb Trauma’ (HOLLT) study which includes 
patients with complex fracture of the lower leg following crush injury (Millar et al, 2015). The 
second, the ‘Hyperbaric oxygen therapy in calcaneal intra-articular fractures: can it decrease 
the soft-tissue complication rate  (HOCIF) trial. A randomised controlled trial (single centre) to 
include approximately 160 people (Knobe, 2011). Thirdly, ‘Hyperbaric oxygen therapy in distal 
radius fractures: can it shorten recovery time and increase fracture healing? (HBOTRadius), to 
include approximately 100 patients (Knobe, 2011). A Cochrane review by Bennett et al, (2012) 
on promotion of fracture healing and treating fracture no union was also located.  
 
The review by Bennett et al, (2012), failed to locate any randomised controlled trials that 
confirmed or refuted the use of HBOT in the treatment of non-union bony fractures and 
delayed bony healing. Of the 11 full text articles found and assessed for eligibility the review 
excluded 5 reviews as they contained no new data. Three RCTs were excluded as two did not 
report on fracture healing outcomes and one had been abandoned. The remaining three 
articles were the three registered trials in progress previously mentioned  
 
A Summary of the review of HBOT as a Treatment for Fractures 
 
Despite HBOT demonstrating potential benefits in animal studies, HBOT has failed to 
demonstrate its effect in the treatment of delayed bony healing and non-union of bony 
fractures in humans (Inoue et al, 2000; Wang et al, 2005). No evidence exists to support of 
refute the use of HBOT. Future evidence to support the use of HBOT may be identified in the 3 
ongoing clinical trials.  
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Conclusion / Recommendations  
 
 
There is an abundance of anecdotal evidence to support the use of HBOT. However, there 
remains a scarcity of detailed randomised controlled trials to support its use.  
As previously described HBOT has guidelines and has been cleared for its safe use in a number 
of conditions with clear evidence of its use in decompression sickness and a small number of 
other conditions.  
No accepted guidelines currently exist for DOMS, closed soft tissue injury, fracture healing or 
treating fracture non-union. Despite this, treatment effects identified in other condition 
provide some promise for the inclusion of these conditions in the use of HBOT. 
Side effects of HBOT have been identified and are usually mild, but in some rare cases may be 
life threatening. However, by ensuring contraindications and precautions are identified and 
correct safety procedures are adhered to problems should not occur and the delivery of HBOT 
be considered as safe 
Research to date has yet still to determine the beneficial physiological, biochemical and cellular 
effects achieved with HBOT. Staples et al, (1999) in the analysis of treatment effect for 
inflammation suggests the need to monitor biochemical markers to determine whether HBOT 
benefits are as a result of inflammatory reduction or as a result of the enhanced healing ability 
of the body. 
Parameters for a number of indications have been suggested.  However, in order to obtain the 
best clinical and cost effective results further work remains to be carried to determine best 
timings, indications and therapeutic protocols.  
It has been suggested that the most beneficial results in previous studies looking at re-
perfusion of ischemic muscle in burn therapy occurs when HBOT is initiated in the first 8 hours 
(Zamboni et al, 1993; Cianci & Sato, 1994). Many studies fail to administer HBOT early enough 
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to gain the most beneficial effect, especially in cases where reduction of inflammation and the 
pain associated with it is considered one of the primary outcomes  
Future research should aim to include well conducted randomised controlled with larger and 
carefully selected sample sizes. More consideration should be given to the correct HBOT timing 
and number of treatments, to help determine the most effective dosage and at what stage of 
treatment.  
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